Key Insights

Highlights

Success Rate

77% trial completion

Published Results

23 trials with published results (25%)

Research Maturity

57 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

18.5%

17 terminated out of 92 trials

Success Rate

77.0%

-9.5% vs benchmark

Late-Stage Pipeline

14%

13 trials in Phase 3/4

Results Transparency

40%

23 of 57 completed with results

Key Signals

23 with results77% success17 terminated

Data Visualizations

Phase Distribution

65Total
Not Applicable (13)
P 1 (19)
P 2 (20)
P 3 (10)
P 4 (3)

Trial Status

Completed57
Terminated17
Recruiting5
Unknown5
Withdrawn4
Active Not Recruiting4

Trial Success Rate

77.0%

Benchmark: 86.5%

Based on 57 completed trials

Clinical Trials (92)

Showing 20 of 20 trials
NCT06481306Phase 1RecruitingPrimary

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT05087303Not ApplicableActive Not RecruitingPrimary

Telemedicine for Children With Sickle Cell Disease

NCT03249831Phase 1Active Not Recruiting

A Blood Stem Cell Transplant for Sickle Cell Disease

NCT06078696Phase 1TerminatedPrimary

Siplizumab for Sickle Cell Disease Transplant

NCT03376893Active Not RecruitingPrimary

Epidemiology of Silent and Overt Strokes in Sickle Cell Disease

NCT06098755Not ApplicableWithdrawn

The Sequestration of Holistic Stress Management Techniques for Adults

NCT06144749Phase 1RecruitingPrimary

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

NCT05451940Phase 1CompletedPrimary

Hydroxyurea and EPO in Sickle Cell Disease

NCT04170348Phase 2Completed

Daily Vitamin D for Sickle-cell Respiratory Complications

NCT04406818Not ApplicableRecruiting

Metabolic and Hemodynamic Reserve in Pediatric SCA

NCT02286154Not ApplicableActive Not RecruitingPrimary

Therapeutic Response Evaluation and Adherence Trial (TREAT)

NCT03926819Phase 1CompletedPrimary

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

NCT02187003Phase 3CompletedPrimary

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT06290401Phase 2RecruitingPrimary

A Socio-ecological Approach for Improving Self-management in Adolescents With SCD

NCT03380351CompletedPrimary

Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)

NCT04420585Phase 4Terminated

Desmopressin for Bedwetting in Children With SCD

NCT04536792Phase 1Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT02186418Phase 1TerminatedPrimary

Gene Transfer for Patients With Sickle Cell Disease

NCT02373241Phase 2TerminatedPrimary

Preventing Sickle Cell Kidney Disease

NCT06250595Recruiting

European Rare Blood Disorders Platform (ENROL)

Scroll to load more

Research Network

Activity Timeline